RedHill Biopharma (RDHL) Return on Assets (2013 - 2024)

RedHill Biopharma (RDHL) has 12 years of Return on Assets data on file, last reported at 0.03% in Q4 2024.

• On a quarterly basis, Return on Assets rose 4.0% year-over-year to 0.03% in Q4 2024; TTM through Dec 2024 was 0.03%, a 4.0% increase from a year earlier, with the FY2025 full-year figure at 0.0%, up 1.0% from the prior year.
• Return on Assets for Q4 2024 stood at 0.03%, up from 0.02% in the prior quarter.
• Over the last five years, Return on Assets for RDHL reached as high as 0.03% in Q4 2024 and fell as low as 0.01% in Q2 2023.
• Historically, Return on Assets has averaged 0.0% across 5 years, with a median of 0.0% in 2021.
• Across the five-year window, Return on Assets fell 1 bps in 2020 and advanced 4 bps in 2024, its largest moves.
• Year by year, Return on Assets stood at 0.0% in 2020, then sank by 243 bps to 0.0% in 2021, then grew by 4 bps to 0.0% in 2022, then tumbled by 41 bps to 0.01% in 2023, then soared by 561 bps to 0.03% in 2024.
• Per Business Quant data, the three most recent Return on Assets figures were 0.03% in Q4 2024, 0.02% in Q2 2024, and 0.01% in Q4 2023.